Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant docetaxel, oxaliplatin plus S-1 for advanced esophageal cancer
jRCTs041210023Phase 2Recruiting
- Sponsor
- Nagoya University Hospital
- Start
- Aug 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, oxaliplatin and tegafur in esophageal cancer, sponsored by Nagoya University Hospital. Primary endpoint: Pathological response rate. Started Aug 2021; status: recruiting.
02
Drugs
docetaxeloxaliplatintegafur
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCTs041210023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210023.